You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和鉑醫藥-B(02142.HK)完成向首名患者以巴託利單抗(HBM9161)II期試驗治療甲狀腺眼病首次給藥
格隆匯 10-19 17:09

格隆匯10月19日丨和鉑醫藥-B(02142.HK)發佈公吿,巴託利單抗(HBM9161,一款由公司開發用於自身免疫性疾病療法的新型藥物,定義詳見下文)用於治療甲狀腺眼病的臨牀II期試驗中,完成了首名患者的首次給藥。該臨牀試驗旨在評估巴託利單抗(HBM9161)在治療中國甲狀腺眼病患者時的療效及安全性。

巴託利單抗(HBM9161)可阻斷免疫球蛋白G(“IgG”)(包括致病性IgG)與新生兒Fc受體(“FcRn”)的結合,並大幅降低體內的IgG水平,從而治療以自身抗體為介導的自身免疫性疾病,包括甲狀腺眼病。作為產品管線的一部分,公司正在開發巴託利單抗(HBM9161),用於治療多種有大量未獲滿足醫療需求的且由致病性IgG介導的自身免疫性疾病。公司正於中國針對適應症開發候選藥物,而甲狀腺眼病為當中首批展開研究的適應症之一。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account